Supreme Court overturns Limelight and Nautilus cases
US Supreme Court agrees to hear Nautilus heart monitor case
Michael Fedorak / Shutterstock.com
A US appeals court has reversed a decision to award $30 million in supplemental damages to The Dow Chemical Company after finding that its patents were invalid under a standard established by the US Supreme Court’s Nautilus v Biosig ruling.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
CAFC; The Dow Chemical Company; Nova Chemicals; indefinite claims; US Supreme Court; Nautilus; Biosig; patents